Drospirenone with 17β-estradiol in the postmenopausal woman with hypertension

Climacteric

Volumn 10, Issue SUPPL. 1, 2007, Pages 25-31

  White, W B ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cardiovascular Disease; Drospirenone; Estrogen Replacement Therapy; Hormone Therapy; Menopause; Progestogen

Indexed keywords

ALDOSTERONE ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE PLUS ESTRADIOL; EPLERENONE; MINERALOCORTICOID RECEPTOR; SODIUM CHLORIDE; SPIRONOLACTONE; WATER; ANDROSTANE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ESTRADIOL; ESTRADIOL DROSPIRENONE COMBINATION; ESTRADIOL-DROSPIRENONE COMBINATION; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BINDING; GYNECOMASTIA; HOMEOSTASIS; HORMONAL THERAPY; HUMAN; HYPERKALEMIA; HYPERTENSION; MENSTRUAL IRREGULARITY; MONOTHERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SODIUM RETENTION; SYMPTOM; WATER RETENTION; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; REVIEW;

ANDROSTENES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERTENSION; POSTMENOPAUSE;

EID: 33847098282     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130601114933     Document Type: Conference Paper

References (37)

1. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000;14:83-90
2. Franklin SS, Gustin W 4th, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997;96:308-15
3. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
4. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
5. MacMahon S. Blood pressure and the prevention of stroke. J Hypertens 1996;14(Suppl):S39-46
6. Staessen JA, Wang J-G, Thijs L. Cardiovascular protection and blood pressure reduction: a metaanalysis. Lancet 2001;358:1305-15
7. Regitz-Zagrosek V. Cardiovascular disease in postmenopausal women. Climacteric 2003;6(Suppl 3):13-20
8. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206
9. Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens 1989;3:427-33
10. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9
11. Whyte JL, Lapuerta P, L'Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J Clin Hypertens 2001;3:211-16
12. Krakoff LR, Phillips RA. White-coat hypertension. Lancet 1996;348:1443-4
13. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood pressure. Lancet 1978;1:795-7
14. White WB. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003;21(Suppl):S9-15
15. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 2006;19:243-50
16. Pickering TG, Hall JE, Appel LJ, et al. Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals. 1. Blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;45:142-61
17. Weber MA. The 24-hour blood pressure pattern: does it have implications for morbidity and mortality? Am J Cardiol 2002;89:27-33A
18. McMahon EG. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001;1:190-6
19. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-45
20. Conlin PR. Interactions of high salt intake and the response of the cardiovascular system to aldosterone. Cardiol Rev 2005;13:118-24
21. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982;4:966-72
22. van de Wal RM, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006;106:367-72
23. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-5
24. de Gasparo M, Whitebread SE, Preiswerk G, Jeunemaitre X, Corvol P, Menard J. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989;32:223-7
25. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
26. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003;92:38-42
27. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung 1985;35:459-71
28. Pollow K, Juchem M, Elger W, et al. Dihydrospirorenone (ZK30595): a novel synthetic progesterone - characterization of binding to different receptor proteins. Contraception 1992;46:561-74
29. Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311-35
30. Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51
31. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 2003;68:891-905
32. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-8
33. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4
34. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716-27
35. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979-84
36. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J Hypertens 2003;21:1011-53
37. White WB, Hanes V, Pitt B, Chauhan V. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006;48:246-53